Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tranzyme shares dive as bowel drug ulimorelin misses PhIII endpoint

This article was originally published in Scrip

Executive Summary

Shares of Tranzyme Pharma plunged after the firm’s lead drug candidate, the intravenous ghrelin agonist, ulimorelin, failed to meet its primary efficacy endpoint of accelerating recovery of GI function versus placebo in the Phase III ULISES 007 trial of subjects who have undergone bowel resection surgery.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel